Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

24-02-2026

Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: “I sidste ende føles det helt rigtigt”

16-01-2026 MedWatch

$160 million Series A round for Alveus

08-01-2026 The Pharma Letter

Alveus Therapeutics exits stealth with $160M, developing an alternative to drugs like Ozempic

08-01-2026 Technical.ly

Alveus launches with $160M as newest start-up to step into obesity fray

08-01-2026 FirstWord Pharma

Obesity biotech Alveus gains $160M for push into MariTide’s backyard — and amylins

08-01-2026 Endpoint News

Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug

08-01-2026 BioSpace

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape

08-01-2026 Fierce Biotech

Alveus Therapeutics, a Philadelphia start-up treating obesity, debuted with $160M in funding

08-01-2026 The Philadelphia Inquirer

Philadelphia VC firm creates obesity drug startup, raises $159.8M Series A

08-01-2026 Philadelphia Business Journal

Alveus raises $160M Series A for obesity drugs

08-01-2026 Axios

Biotech Alveus raises $160 million to tackle weight loss maintenance

08-01-2026 Reuters

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

23-01-2026

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

08-01-2026